KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.

  • Travere Therapeutics' Profit After Tax rose 14689.93% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7480.78%. This contributed to the annual value of -$321.5 million for FY2024, which is 1455.84% up from last year.
  • Per Travere Therapeutics' latest filing, its Profit After Tax stood at $25.7 million for Q3 2025, which was up 14689.93% from -$12.8 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Profit After Tax peaked at $150.7 million during Q3 2023, and registered a low of -$136.1 million during Q1 2024.
  • For the 5-year period, Travere Therapeutics' Profit After Tax averaged around -$54.6 million, with its median value being -$70.4 million (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Profit After Tax crashed by 676670.79% in 2021, and later surged by 27931.19% in 2023.
  • Over the past 5 years, Travere Therapeutics' Profit After Tax (Quarter) stood at -$88.8 million in 2021, then increased by 3.53% to -$85.6 million in 2022, then decreased by 5.3% to -$90.2 million in 2023, then skyrocketed by 33.17% to -$60.3 million in 2024, then skyrocketed by 142.66% to $25.7 million in 2025.
  • Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.